DEBORAH RUSH: Open Payments
NPI 1518209196 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,973 in 125 payments from 14 companies in 2025. Trend: 2023 $2,875 · 2024 $3,169 · 2025 $2,973
Food & beverage: $2,901Education: $71
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $435 |
| E.R. Squibb & Sons, L.L.C. | 11 | $400 |
| Teva Pharmaceuticals USA, Inc. | 10 | $375 |
| ABBVIE INC. | 30 | $363 |
| Vanda Pharmaceuticals Inc. | 15 | $319 |
| Alkermes, Inc. | 13 | $318 |
| Otsuka America Pharmaceutical, Inc. | 11 | $226 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $196 |
| Janssen Pharmaceuticals, Inc | 4 | $116 |
| Corium, LLC | 4 | $79 |
Products named: INGREZZA, COBENFY, FANAPT, VRAYLAR, LYBALVI, REXULTI, CAPLYTA, UZEDY.
Industry payments across ID — which companies pay providers there.
